期刊文献+

荧光原位杂交技术在膀胱尿路上皮肿瘤病理学诊断中的初步应用 被引量:4

Preliminary Application of Fluorescence in Situ Hybridization in Pathological Diagnosis of Bladder Urothelial Tumor
下载PDF
导出
摘要 目的应用荧光原位杂交(fluorescence in situ hybridization,FISH)技术,了解膀胱尿路上皮肿瘤细胞核染色体畸变情况及其对病理诊断及鉴别诊断的应用价值。方法采用3、7、17号染色体着丝粒及p16基因探针,对33例不同级别膀胱尿路上皮肿瘤组织和10例正常对照膀胱组织进行FISH检测。结果 3、7、17染色体及p16扩增率与缺失率,浸润性尿路上皮癌与其他5组比较均有统计学意义(P<0.01);而其他各组间比较无统计学意义(P>0.05),4种探针联合检测≥2个指标出现异常,浸润性尿路上皮癌占100%,与其他5组比较有统计学意义(P<0.01);该指标对浸润性尿路上皮癌诊断敏感性为81.82%、特异性为91.67%。结论应用FISH技术,可以了解膀胱尿路上皮肿瘤组织3、7、17染色体及p16基因的畸变情况,FISH技术还可作为尿路上皮肿瘤病理学诊断与鉴别诊断及术后监测的重要手段。 Objective To investigate the value of fluorescence in situ hybridization(FISH)for detecting the chromosome aberration and diagnosis and differential diagnosis of urothelial tumors.Methods 3,7,17 chromosome and p16 gene were analyseed by FISH in 33 urothelial tumor specimens and 10 normal bladder tissues.Results The positive rate of 3,7,17 chromosome and p16 genes amplification and p16 gene deletion in invasive urothelial cancer were significantly higher than other 5 groups of urothelial tumors(P〈0.01).All of invasive urothelial carcinoma showed more than two abnormal indexes Sensitivity and specificity of more than two abnormalindexes in diagnosis of invasive urothelial cancer was 81.82% and 91.67% respectively.Conclusion FISH can be used for analyzing 3,7,17 chromosome and p16 gene amplification and diagnosis/differential diagnosis in urothelial tumors.
出处 《实用癌症杂志》 2011年第5期441-443,447,共4页 The Practical Journal of Cancer
基金 卫生部科研资助项目(WKJ2007-3-001)
关键词 荧光原位杂交 尿路上皮肿瘤 染色体 病理组织 Fluorescence in situ hybridization(FISH) Urothelial tumors Chromosome Histopathological
  • 相关文献

参考文献10

  • 1马春雷,司今,戴聪,张建永,李锦毅.膀胱癌荧光原位杂交检测及其临床意义[J].中国肿瘤临床,2009,36(23):1329-1332. 被引量:4
  • 2Gerr H,Gadzicki D,Kreipe H,et al.Fluorescence in situ hybridization reveals closely correlated results in cytological and histological specimens of hematological neoplasias comped to conventional Cytogenetics[J].Pathobiology,2006,73(6):271.
  • 3Krause FS,Rauch A,Schrott DG.Clinical decisions for tre-atment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays[J].World J Urol,2006,24(3):418.
  • 4Prout GR,Barton BA,Griffin PP,et al.Treated history of noninvasive grade 1 transitional cell carcinoma.The National Bladder Cancer Group[J].J Urol,1992,148(5):1413.
  • 5Sandberg AA,Berger CS.Review of chromosome studies in urological Tumors.Ⅱ.Cytogenetics and molecular genetics of bladder cancer[J].J Urol,1994,15l(3):545.
  • 6Tobias Z,Gabriel B,Gieri C,et al.Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer[J].Int J Cancer,2006,119:1660.
  • 7Jones JS.DNA-based molecular cytology for bladder cancer surveillance[J].Urology,2006,67(3):35.
  • 8Matin-Aguilera M,Mengual L,Ribal MJ,et al.Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma[J].Eur Urol,2007,51(2):409.
  • 9Luo B,Li W,Deng CH,et al.Utility offluorescence in situ hy-bridization in the diagnosis of upper urinary tract urothelial carcinoma[J].Cancer Genet Cytogenet,2009,189(2):93.
  • 10Bollmann M,Heller H,Bankfalvi A,et al.Quantitative molecular urinary cytology by fluorescence in situ hybridization:a tool for tailoring surveillance of patients with superficial bladder cancer[J].BJU Int,2005,95(9):1219.

二级参考文献13

  • 1Sandberg AA, Berger CS. Review of chromosome studies in urological tumors . Ⅱ. Cytogenetics and molecular genetics of bladder cancer[J].J Urol, 1994, 151(3): 545 -560.
  • 2Pinkel D, Straume T, GrayJW. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization[J]. Proc Natl Acad Sci U S A, 1986, 83(9): 2934-2938.
  • 3Hailing KC, King W, Sokolova IA, et al.A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma[J].J Urol, 2000, 164(5): 1768-1775.
  • 4Zhang J, Zheng S, Gao Y, et al. A partial allelotyping of urothelial carcinoma of bladder in the Chinese[J]. Carcinogenesis, 2004, 25 (3): 343-347.
  • 5Qin SL, Chen XJ, Xu X, et al. Detection of chromosomal alterations in bladder transitional cell carcinomas from Northern China by comparative genomic hybridization[J]. Cancer Lett, 2006, 238 (2): 230-239.
  • 6Kruger S, Mess F, Bohle A, et al. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence m urinary bladder[J]. transitional cell carcinoma of the IntJ Oncol, 2003, 23(1): 41-48.
  • 7Degtyar P,Neulander E,Zirkin H, et al. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional ceil carcinoma of the bladder[J]. Urology, 2004, 63 (2):398-401.
  • 8Mhawech-Fauceglia P, Fischer G, Beck A, et al. Rafl,Aurora-A/ STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up[J]. Eur J Surg Oncol, 2006, 32(4):439-444.
  • 9Gallucci M,Guadagni F, Marzano R, et al. Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters[J].J Clin Pathol, 2005, 58(4):367-371.
  • 10Marin-Aguilera M, Mengual L, Ribal MJ, et al. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer[J]. Cancer Genet Cytogenet, 2007, 173(2): 131-135.

共引文献3

同被引文献18

  • 1Cianciulli AM,Leonardo C,Guadagni F. Genetic insta-bility in superficial bladder cancer and adjacent mucosa:an interphase cytogenetic study[J].{H}Human Pathology,2003,(03):214-221.
  • 2Bocsi J,Perner F,Szücs J. DNA content of parathyroid tumors[J].{H}Anticancer Research,1998,(4B):2901-2904.
  • 3Matturri L,Biondo B,Cazzullo A. Prognostic significa-nce of different biological markers (DNA index,PCNA in-dex,apoptosis,p53,karyotype) in126 adenocarcinoma gastric biopsies[J].{H}Anticancer Research,1998,(4B):2819-2825.
  • 4Faranda A,Costa A,Canova S. Image and flow cytomet-ric analyses of DNA content in human solid tumors.A com-parative study[J].{H}Analytical and Quantitative Cytology and Histology,1997,(04):338-344.
  • 5Luo B,Li W,Deng CH. Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma[J].{H}Cancer Genetics Cytogenetics,2009,(02):93-97.
  • 6Marín-Aguilera M,Mengual L,Ribal MJ. Utility of a multiprobe fluorescence in situ hybridization assay in the de-tection of superficial urothelial bladder cancer[J].{H}Cancer Genetics Cytogenetics,2007,(02):131-135.
  • 7Lamm DL. Prophylaxis for recurrent transitional cell carci- noma[ J]. Urology, 1991,37 (5 suppl ) :21-23.
  • 8Solsona E, Climent MA, Iborra I, et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurthral resection of the bladder plus systemic chemotherapy : long-term follow-up a phase 2 nonrandomized comparative trial with radical cystectomy [ J ]. Eur Urol, 2009,55(4) :911-919.
  • 9Modak S, Kramer K, Ciuliekin SH, et al. Monoclonal antit- body 8H9 targets a novel cell surface antigen expressed by a wide spetrum of human solid tumors [J].Cancer Res, 2001,61 (10) :4048-4054.
  • 10Kurihara N, Kubota T, Hoshiya Y, et al. Antitumor activity of cisdaiamminedichloroplatinum ( II ) depends on its time X concentration product against human gastric cancer cell lines in vitro[J]. J Surg Oncol, 1995,60 (4) :238-241.

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部